Continue current treatment: strontium ranelate

Strontium ranelate is associated with an increased risk of VTE. Results from population-based studies and post-marketing surveillance show that this risk is higher in patients with a history of VTE, as well as in patients who are temporarily or permanently immobilized. Therefore strontium ranelate must not be used in these patients. Based on the recommendation for thromboembolism prophylaxis for 35 days after a hip fracture, a higher risk for fracture patients over 35 days may be expected.

Furthermore, in order to reduce the risk of heart attack, strontium ranelate must also not be used in patients with high blood pressure that is not properly controlled or in patients with a current or past history of any of the following:

Although two recent studies did not confirm the higher risk for cardiovascular events in patients treated with strontium ranelate, the majority of older adults with osteoporosis have conditions that are now considered as contraindications according to the EMA. For these reasons, strontium ranelate is recommended only in patients without any acceptable alternative treatment options.

Literature